LAUSR

Solid organ transplantation represents the ultimate therapeutic option for terminal organ failure and has experienced a tremendous success in the last decades. However, major problems, such as the risks associated with life-long immunosuppression, have not been resolved so far. These risks are mainly three-fold: (i) infections (usual and opportunistic ones), (ii) increased cancer incidence, and (iii) cardiovascular complications (newly induced or aggravated by chronic immunosuppression) (1). There is also a close relation between infection and cancer, since certain viruses directly cause cancers such as post-transplant lymphoproliferative disorder (PTLD; mainly caused by Epstein-Barr virus, EBV), cervical cancer (papillomavirus) or Kaposi sarcoma (human herpesvirus 8) (2). This article is protected by copyright. All rights reserved.